| Cash and cash equivalents |
129.17K |
| Trade, net of allowance for doubtful accounts of $8,000 at June 30, 2011 and September 30, 2010 |
220.67K |
| Inventories |
399.96K |
| Unbilled receivables |
28.42K |
| Deferred finance costs |
8.6K |
| Prepaid expenses and other current assets |
183.1K |
| Total current assets |
1M |
| Goodwill |
| Intangible assets |
4.41K |
| Furniture, equipment and leasehold improvements, net |
965.16K |
| Deferred finance costs, less current portion |
| Other assets |
610.12K |
| TOTAL ASSETS |
2.58M |
| Current maturities of convertible long-term debt |
16.86M |
| Current maturities of other long-term debt |
28.57M |
| Accounts payable |
1.18M |
| Accrued expenses |
1.1M |
| Accrued interest |
4.71M |
| Reserve for unresolved claims |
| Unearned revenues |
| Notes payable, related parties |
| Customer deposits |
0 |
| Derivative liability |
1.04M |
| Total current liabilities |
55.96M |
| Long-term convertible promissory notes, net of current maturities |
| Convertible promissory notes, related party |
| Other long-term debt |
13.27M |
| Long-term accrued interest |
| Liabilities subject to compromise |
| Total liabilities |
82.32M |
| Commitments and contingencies |
0 |
| Series A convertible redeemable preferred stock, $1.00 par value; no shares issued and outstanding and 8,950 authorized as of June 30, 2011; 7,529 shares issued and outstanding and 8,950 authorized as of September 30, 2010 |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 72,441,000 shares issued and 70,892,864 shares outstanding at June 30, 2011, and 58,243,115 shares issued and 58,048,208 shares outstanding at September 30, 2010 |
90.21K |
| Treasury stock, 1,548,136 and 194,907 shares, June 30, 2011 and September 30, 2010 |
-1.5M |
| Additional paid-in capital |
276.47M |
| Accumulated deficit |
-338.19M |
| Total stockholders' deficit attributable to Accentia Biopharmaceuticals, Inc. |
-63.13M |
| Non-controlling interests |
-16.61M |
| Total stockholders' deficit |
-79.74M |
| Total liabilities and stockholders' deficit |
2.58M |
